These trials suggested that non-selective inhibition of TNF-α is harmful in MS and that TNF-α exerts both potent pro-inflammatory effects and essential protective functions in the CNS under pathological conditions [9••]. The gene discussed is TNF; the disease is myeloid sarcoma.